Figure 4.

β2-adrenoceptors and NF-κB involvement in the effects of salmeterol on asthmatic (A) ASMC. The effects of lower salmeterol concentrations on A) CXCL10 release in the presence or absence of the selective β2-adrenoceptor antagonist butoxamine 30 μM or its vehicle, or B) IκB-α degradation (a representative immunoblot from 1 of 4 different ASMC examined) and C) NF-κB p65 DNA binding activity by confluent serum-deprived cells stimulated with cytomix for 24 h (A), or up to 30 min (B and C), were determined. Butoxamine was added to the cells 1 h before salmeterol. US, unstimulated; cyt, cytomix.